Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.
Y, H., P, Y., T, W., S, Y., P, H., & Z, L. (2026). Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.. Scientific reports. https://doi.org/10.1038/s41598-026-51909-w
Y H, P Y, T W, S Y, P H, Z L. Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.. Scientific reports. 2026; doi: 10.1038/s41598-026-51909-w
Y H, P Y, T W, et al. Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.[J]. Scientific reports. 2026. DOI: 10.1038/s41598-026-51909-w.
@article{y2026,
author = {Huo Y and Yu P and Wang T and Yang S and Han P and Li Z},
title = {Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors.},
journal = {Scientific reports},
year = {2026},
doi = {10.1038/s41598-026-51909-w},
note = {PMID: 42477364},
}
TY - JOUR AU - Huo Y AU - Yu P AU - Wang T AU - Yang S AU - Han P AU - Li Z TI - Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors. T2 - Scientific reports PY - 2026 DO - 10.1038/s41598-026-51909-w AN - PMID:42477364 ER -
Albumin-bound paclitaxel (Abraxane) exhibits potent antitumor activity, but its suboptimal pharmacokinetics and the restrictive blood-brain barrier (BBB) greatly limit the broader application of albumin-based paclitaxel formulations in intracranial tumors. In this work, we engineered size-uniform (~ 160 nm) paclitaxel-albumin nanoparticles (Fe3+@SA-PTX) via simple one-step nano-precipitation method guided by a "protein corona intervention" strategy. During nanoparticle fabrication, tannic acid-Fe3+ (TA-Fe3+) were strategically introduced. On the one hand, the introduction of TA-Fe3+ shell could slow down the leakage of paclitaxel and improving the stability and pharmacokinetic profile of the nanoparticles. On the other hand, the presence of Fe3+ enabled the nanoparticles to interact with unsaturated transferrin in plasma, forming a stable transferrin protein corona. This endowed the nanoparticles with enhanced tumor-targeting capability and the ability to penetrate the BBB. The Fe3+@SA-PTX exhibited superior pharmacokinetics and therapeutic efficacy against intracranial tumors via intravenous administration.